NEOSTIGMINE RENAUDIN 5 mg/5 ml, solution for injection 10 ampoules of 5 ml
Active ingredients: Neostigmine methylsulfate
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection10 ampoules of 5 mlintramusculaire;intraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NEOSTIGMINE RENAUDIN 5 mg/5 mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire;intraveineuse;sous-cutanée
- Presentation description
- 10 ampoule(s) en verre de 5 ml
- Marketing authorisation holder
- LABORATOIRE RENAUDIN
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Sept 2013
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62036900CIP72693958CIP133400926939588Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉTILSULFATE DE NÉOSTIGMINEsolution | 5 mg · une ampoule de 5 mL de solution injectable | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.